WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Technology Internet Technology Thursday, December 13, 2018 
Add Press Release News | News Feeds Feeds | Email This News Email

BDD Appoints Ex-AstraZeneca VP Joanne Kelley as Non-executive Director to the Board
Friday, October 12, 2018

GLASGOW, Scotland, October 12, 2018 /PRNewswire/ --

BDD today announced the appointment of Joanne Kelley as Non-executive Director of the Board.

Jo is a Life Sciences Business Development professional and brings an outstanding track record of strategy development, deal preparation and execution to the BDD Board.

During a long, successful career at AstraZeneca, Jo had extensive experience of global commercial and general management. In the role of Vice President of Business Development, Head of Transactions at AstraZeneca, Jo was responsible for a number of transformational deals. She has led all types of transactions including M&A, technology licensing and collaboration arrangements. Jo has received a number of awards recognising her deal making achievements from colleagues and peers including recognition from The Pharmaceutical Licensing Group.

After retiring from AstraZeneca Jo has continued to pursue her passion to support UK innovation. She now works as a Director of Alderley Park Ventures and is a non executive director at UMI3, the innovation company of Manchester University.

Commenting on this appointment, Howard Stevens, Chairman of BDD, said: "I am delighted to welcome Jo to the Board, she brings a broad range of experience to the role, including significant licensing experience. I am certain she will play a big part in BDD's future success as we continue to grow and expand our licensing and collaboration activities."

Commenting on her appointment, Jo said "I am delighted to be joining the Board of BDD at such an exciting time in the company's expansion. BDD is an innovative and ambitious company with a lot to offer pharma partners."

Notes to Editors 

About BDD 

BDD Pharma Ltd is a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations. BDD's OralogiK(TM) technology is a tablet-in-tablet drug delivery system providing timed release, sustained release and the opportunity for complex bi- and tri-phasic release of one or multiple drugs. The OralogiK(TM) technology is protected with granted patents in the US, EU and Japan. Supported by investment from Archangels and the Scottish Investment Bank, BDD has in house clinical trial capabilities for the conduct of gamma scintigraphic/ pharmacokinetic studies in humans.

For more information visit [ ]


Email This News Email | Submit To Slashdot Slashdot | Submit To Digg | Submit To | News Feeds Feeds

Nav PINTEC enables Zhejiang Rural Credit Cooperatives with Robo-advisory solution | Dec 13, 2018
Nav ISLE 2019 Set to Gather Thousands of SIGN & LED industry Leaders in China | Dec 13, 2018
Nav Warm Materials Inc. is Looking to Turn Back Time With Its Newest Kickstarter Product, WOODSUM Pinhole Camera | Dec 13, 2018
Nav Florida Technical College Selects Private Eyes to Provide Background Checks | Dec 13, 2018
Nav H&D Wireless Selected by Skanska to Increase Security in the Construction Industry Using the Internet of Things | Dec 13, 2018
Nav LF Deep Learning Welcomes Horovod Distributed Training Framework as Newest Project | Dec 13, 2018
Nav VIDORA Gives Leading Businesses a Boost Through Self-Service Machine Learning | Dec 13, 2018
Nav BaseHealth Launches First Predictive Analytics Platform Using Patient Laboratory Data to Reveal Hidden Health Risks | Dec 13, 2018
Nav Skateboarding Legend Tony Hawk Returns To Gaming With Best-In-Class Mobile Game: Tony Hawk's Skate Jam | Dec 13, 2018
Nav accesso® and Merlin Entertainments Take Long-Standing Partnership to New Heights at The Bear Grylls Adventure | Dec 13, 2018

Submit News | View More News View More News